Y. Satoh*

发表

SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase

David W. Anderson, A. Manning, Y. Satoh, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Pro-inflammatory signaling by Jun-N-terminal kinase in inflammatory bowel disease.

M. Sata, K. Mitsuyama, A. Suzuki, 2006, International journal of molecular medicine.

Activation of c‐Jun N‐terminal kinase (JNK) signalling in experimentally induced gastric lesions in rats

M. Sata, K. Mitsuyama, A. Suzuki, 2006, Clinical and experimental immunology.

JNK: a new therapeutic target for diabetes.

Y. Satoh, B. Bennett, A. Lewis, 2003, Current opinion in pharmacology.

Inhibitors of the MAPK pathway

Y. Satoh, B. Stein, B. Murray, 2000 .

Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury.

Y. Satoh, B. Bennett, D. Giegel, 2012, Bioorganic & medicinal chemistry letters.

Augmentation of the inhibitory effect of FK480, a CCK-A receptor antagonist, on pancreatic exocrine secretion by achlorhydria.

Y. Satoh, T. Matsuo, M. Kuno, 1998, Pancreas.

A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor

K. Nishikawa, S. Horie, Y. Satoh, 2014, Molecular Cancer Therapeutics.

ANovel Compound , NK 150460 , Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor

K. Nishikawa, S. Horie, Y. Satoh, 2015 .

JNK mediates hepatic ischemia reperfusion injury.

D. Brenner, G. K. Bilter, J. Westwick, 2005, Journal of hepatology.

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.

Chin-Chun Lu, Y. Satoh, L. LeBrun, 2017, Journal of medicinal chemistry.

Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.

T. Kowalski, Y. Satoh, J. Stanton, 1993, Journal of medicinal chemistry.

Synthesis of optically active .beta.-lactams by the photolytic reaction of imines with optically active chromium carbene complexes

Y. Satoh, L. Hegedus, D. Dvořák, 1990 .

Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor.

Philip Chamberlain, Y. Satoh, B. Bennett, 2012, Bioorganic & medicinal chemistry letters.

Suppression of Alloreactivity and Allograft Rejection by SP600125, a Small Molecule Inhibitor of c-Jun N-terminal Kinase

Y. Satoh, B. Bennett, N. Sato, 2007, Transplantation.

beta-Catenin alteration in cancer of the ampulla of Vater.

T. Furuhata, Y. Kimura, M. Kawakami, 2002, Journal of experimental & clinical cancer research : CR.

Organic synthesis using haloboration reaction, II. A stereo- and regioselective synthesis of [Z]-1-Alkynyl-2-halo-1-alkenes

Y. Satoh, S. Hara, A. Suzuki, 1983 .

Organic synthesis using haloboration reactions 11. A formal carboboration reaction of 1-alkynes and its application to the di- and trisubstituted alkene synthesis

Y. Satoh, N. Miyaura, S. Hara, 1988 .

Structural study of a cell-wall mannan of Saccharomyces kluyveri IFO 1685 strain. Presence of a branched side chain and beta-1,2-linkage.

Y. Satoh, S. Suzuki, N. Shibata, 1993, European journal of biochemistry.

Benzoxepin and benzothiepin derivatives as potent, orally active inhibitors of 5-lipoxygenase

T. Kowalski, Y. Satoh, A. Libby, 1994 .

Evaluating breast cancer risk: available models to assess individual breast cancer risk and probability to be a BRCA mutation carrier.

T. Furuhata, Y. Kimura, Y. Yanai, 2002 .

Synthesis of Sulfonic Acid Functionalized Silica Honeycombs

Y. Satoh, S. Mukai, I. Ogino, 2013 .

Inhibition of LTB4 biosynthesis in situ by CGS 23885, a potent 5-lipoxygenase inhibitor, correlates with its pleural fluid concentrations in an experimentally induced rat pleurisy model

T. Kowalski, Y. Satoh, J. Peppard, 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.